Chorioretinal scars

H7_CHORSCAR

No definition available.

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps	FinnGen
Phenotype data	519870
1. Apply sex-specific rule None	519870
2. Check conditions None	519870
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — H31.0 Hospital discharge: ICD-9 — 3633 Cause of death: ICD-10 — H31.0 Cause of death: ICD-9 — 3633 2 out of 7 registries used, show all original rules.	138
4. Check minimum number of events None	138
5. Include endpoints None	138
6. Filter based on genotype QC (FinnGen only)	131

Control definitions (FinnGen only)

Control exclude: H7_CHOROIDRETINA

Extra metadata

Level in the ICD hierarchy: 4
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: H31
Name in latin: Cicatrices chorioretinales

NAME	H7_CHORSCAR
CONTROL_EXCLUDE	H7_CHOROIDRETINA
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	H310
HD_ICD_9	3633
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	H310
COD_ICD_9	3633
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Chorioretinal scars based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	911	460	444
Only index persons	847	431	416
Unadjusted period prevalence (%)
Whole population	0.01	0.01	0.01
Only index persons	0.02	0.02	0.02
Median age at first event (years)
Whole population	54.06	57.19	50.81
Only index persons	53.76	57.06	50.34

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	131	78	53
Unadjusted period prevalence (%)	0.03	0.03	0.02
Median age at first event (years)	60.37	60.58	60.06

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
138: Matched controls
1380

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

H31.0

ICD-10 Finland

Chorioretinal scars

+∞

196.2

137

XCW99

NOMESCO Finland

Other investigative procedure of eye

7.5

18.5

CK2X4

NOMESCO Finland

Optical coherence tomography (OCT) of ocular fundus

7.1

17.0

CK2S4

NOMESCO Finland

Plain photography of ocular fundus

8.4

16.2

H35.39

ICD-10 Finland

Degeneration of macula and posterior pole

65.2

10.8

XCK10

NOMESCO Finland

Photography of fundus of eye

4.6

10.3

H33.0

ICD-10 Finland

Retinal detachment with retinal break

+∞

9.5

CKD05

NOMESCO Finland

Puncture of vitreous body with injection of medication

39.5

9.2

Z96.1

ICD-10 Finland

Presence of intraocular lens

3.7

8.2

H35.31

ICD-10 Finland

Senile macular degeneration (atrophic)(exudative)

84.4

7.5

H33.3

ICD-10 Finland

Retinal breaks without detachment

+∞

7.4

TimeCodeWAS

↥

TODO / Current known limitations:

Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
Legend / how to read the glyphs.
Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
Download CSV.
No filters and sorters.
Limited amount of endpoints (~400) having TimeCodeWAS data.
Cross-links to Risteys lab test pages for lab test codes.

OMOP concept

ln(OR)

%cases with code / %controls with code

2×2 table

Ophthalmology
18 [38004463]

1.2e+00

2.1e+00

2.2e+00

—

2.9e+00

2.5e+00

1.4e+00

cases:29.63%

controls:10.92%

cases:28.68%

controls:4.89%

cases:9.56%

controls:1.11%

—

cases:16.18%

controls:1.04%

cases:33.08%

controls:3.84%

cases:42.02%

controls:14.69%

147

1199

1285

123

1336

—

114

1333

1251

167

970

Outpatient Visit
OP [9202]

4.7e-01

9.7e-01

6.8e-01

5.3e+00

1.8e+00

1.0e+00

1.6e+00

cases:76.30%

controls:66.79%

cases:70.59%

controls:47.74%

cases:19.12%

controls:10.66%

cases:58.82%

controls:0.67%

cases:36.03%

controls:8.61%

cases:72.18%

controls:48.65%

cases:94.12%

controls:77.22%

103

899

447

645

706

144

110

1207

1342

116

1231

633

668

112

878

259

Supplier / Service Provider
OMOP5117446 [33004]

-9.0e-01

-4.0e-01

—

2.5e+00

2.9e+00

cases:11.85%

controls:24.89%

cases:5.15%

controls:7.48%

—

cases:9.02%

controls:0.77%

cases:17.65%

controls:1.14%

335

119

1011

101

129

1250

—

121

1291

1124

Case Management Agency
251B00000X [38004193]

1.4e-01

2.7e-01

7.6e-01

3.7e+00

5.3e-01

2.3e-01

cases:62.96%

controls:59.58%

cases:58.09%

controls:51.44%

cases:35.29%

controls:20.36%

cases:31.62%

controls:1.18%

cases:31.62%

controls:21.46%

cases:58.65%

controls:53.04%

cases:75.63%

controls:71.15%

802

544

695

656

275

1076

1335

289

1058

690

611

809

328

Scheduled procedure
ZXD10 [2001311387]

1.0e+00

1.1e+00

—

1.9e+00

1.2e+00

cases:13.33%

controls:5.20%

cases:4.41%

controls:1.55%

—

cases:7.52%

controls:1.23%

cases:11.76%

controls:3.96%

117

1276

130

1330

—

123

1285

105

1092

Emergency Room Visit
ER [9203]

1.5e-01

6.4e-01

—

1.0e+50

2.2e+00

1.0e+00

8.0e-01

cases:32.59%

controls:29.35%

cases:19.85%

controls:11.55%

—

cases:5.15%

controls:0.00%

cases:8.09%

controls:0.97%

cases:21.80%

controls:9.22%

cases:45.38%

controls:27.18%

395

951

156

109

1195

—

129

1351

125

1334

120

104

1181

309

828

Inpatient Hospital
21 [8717]

3.7e-01

5.8e-01

—

1.6e+00

1.1e+00

5.2e-01

cases:38.52%

controls:30.16%

cases:15.44%

controls:9.25%

—

cases:7.35%

controls:1.56%

cases:21.80%

controls:8.84%

cases:30.25%

controls:20.58%

406

940

125

115

1226

—

126

1326

115

104

1186

234

903

Abdominal ultrasound examination
JN3AE [2001305555]

—

2.3e+00

—

cases:8.40%

controls:0.88%

—

109

1127

Subjective visual disturbances
H53.1 [45557467]

—

2.3e+00

—

cases:7.56%

controls:0.79%

—

110

1128

More than one and less than three hours
ZXE10 [2001311401]

7.8e-01

5.9e-01

—

2.2e+00

9.3e-01

cases:10.37%

controls:5.05%

cases:3.68%

controls:2.07%

—

cases:6.02%

controls:0.69%

cases:9.24%

controls:3.87%

121

1278

131

1323

—

125

1292

108

1093

Senile nuclear cataract
H25.1 [45581628]

8.1e-01

—

1.0e+50

—

2.2e+00

2.8e-01

cases:5.19%

controls:2.38%

—

cases:3.68%

controls:0.00%

—

cases:4.51%

controls:0.54%

cases:5.04%

controls:3.87%

128

1314

—

131

1351

—

127

1294

113

1093

Optical coherence tomography (OCT) of ocular fundus
CK2X4 [2001301456]

—

1.0e+50

—

2.1e+00

—

cases:5.88%

controls:0.00%

—

cases:5.04%

controls:0.62%

—

128

1351

—

113

1130

Exposure to other specified factors
X58 [45756411]

—

2.1e+00

—

cases:5.04%

controls:0.62%

—

113

1130

Migraine with aura [classical migraine]
G43.1 [45562086]

—

2.1e+00

—

cases:5.04%

controls:0.62%

—

113

1130

Lymphocytes/Leukocytes in Blood
26478-8 [3002030]

-2.4e-01

1.2e-01

—

1.2e+00

9.4e-01

cases:7.41%

controls:9.21%

cases:6.62%

controls:5.92%

—

cases:3.68%

controls:1.11%

cases:13.53%

controls:4.61%

cases:24.37%

controls:11.17%

124

125

1222

127

1271

—

131

1332

115

1241

127

1010

Neutrophils/Leukocytes in Blood
26511-6 [3018010]

-6.1e-02

2.0e-02

—

1.2e+00

1.1e+00

8.2e-01

cases:8.15%

controls:8.62%

cases:5.88%

controls:5.77%

—

cases:3.68%

controls:1.11%

cases:12.78%

controls:4.46%

cases:21.85%

controls:10.99%

116

124

1230

128

1273

—

131

1332

116

1243

125

1012

Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]

6.1e-01

1.9e+00

—

9.5e-01

cases:4.44%

controls:2.45%

cases:5.88%

controls:0.89%

—

cases:9.24%

controls:3.78%

129

1313

128

1339

—

108

1094

dexamethasone; oral, parenteral
H02AB02 [21602730]

—

1.9e+00

—

8.0e-01

—

cases:5.15%

controls:0.81%

—

cases:5.88%

controls:2.73%

—

129

1340

—

112

1106

Lymphocytes [#/volume] in Blood
26474-7 [3019198]

-3.7e-01

-5.9e-02

—

1.2e+00

1.0e+00

8.2e-01

cases:7.41%

controls:10.40%

cases:5.88%

controls:6.22%

—

cases:3.68%

controls:1.19%

cases:13.53%

controls:5.23%

cases:24.37%

controls:12.40%

140

125

1206

128

1267

—

131

1331

115

1233

141

996

Bacteria identified in Blood by Culture
600-7 [3023368]

3.5e-01

—

1.7e+00

7.9e-01

cases:5.19%

controls:3.71%

—

cases:9.02%

controls:1.69%

cases:10.08%

controls:4.84%

128

1296

—

121

1279

107

1082

Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]

—

1.7e+00

—

cases:7.56%

controls:1.41%

—

110

1121

One hour or less
ZXE00 [2001311394]

7.2e-01

1.7e+00

—

1.7e+00

1.1e+00

cases:10.37%

controls:5.35%

cases:8.09%

controls:1.55%

—

cases:5.26%

controls:1.00%

cases:10.08%

controls:3.69%

121

1274

125

1330

—

126

1288

107

1095

Office Visit
OMOP4822458 [581477]

7.5e-01

1.7e+00

—

1.4e+00

8.7e-01

cases:13.33%

controls:6.76%

cases:6.62%

controls:1.33%

—

cases:7.52%

controls:2.00%

cases:11.76%

controls:5.28%

117

1255

127

1333

—

123

1275

105

1077

Psychiatry
26 [38004469]

7.9e-01

1.1e+00

—

1.7e+00

1.1e+00

cases:9.63%

controls:4.61%

cases:6.62%

controls:2.22%

—

cases:8.27%

controls:1.69%

cases:10.92%

controls:4.05%

122

1284

127

1321

—

122

1279

106

1091

Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]

—

1.6e+00

—

cases:7.56%

controls:1.58%

—

110

1119

Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]

-5.7e-01

—

1.6e+00

4.3e-01

cases:3.70%

controls:6.39%

—

cases:6.77%

controls:1.46%

cases:10.92%

controls:7.39%

130

1260

—

124

1282

106

1053

Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]

—

1.5e+00

—

cases:10.08%

controls:2.46%

—

107

1109

Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]

—

1.4e+00

—

cases:8.40%

controls:2.11%

—

109

1113

Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]

—

1.4e+00

—

cases:8.40%

controls:2.20%

—

109

1112

Thorax X-ray examination
GD1AA [2001303617]

5.3e-02

7.4e-01

—

1.1e+00

1.3e+00

cases:8.89%

controls:8.47%

cases:5.15%

controls:2.52%

—

cases:6.02%

controls:2.15%

cases:26.05%

controls:8.53%

114

123

1232

129

1317

—

125

1273

1040

Pharmacy visit
OMOP4822462 [581458]

9.8e-01

8.8e-01

3.4e-01

1.0e+00

4.3e-01

1.3e+00

1.0e+50

cases:97.78%

controls:94.28%

cases:93.38%

controls:85.42%

cases:55.15%

controls:46.78%

cases:6.62%

controls:2.44%

cases:56.62%

controls:45.81%

cases:95.49%

controls:84.93%

cases:100.00%

controls:95.07%

132

1269

127

1154

197

632

719

127

1318

617

730

127

1105

196

119

1081

Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]

—

1.3e+00

—

cases:10.08%

controls:2.90%

—

107

1104

Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]

—

1.7e+00

—

2.0e+00

1.3e+00

—

cases:3.68%

controls:0.67%

—

cases:3.76%

controls:0.54%

cases:10.08%

controls:2.90%

—

131

1342

—

128

1294

107

1104

Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]

2.5e-01

1.3e+00

—

7.6e-01

6.9e-01

cases:5.93%

controls:4.68%

cases:8.09%

controls:2.29%

—

cases:5.26%

controls:2.54%

cases:15.13%

controls:8.18%

127

1283

125

1320

—

126

1268

101

1044

quetiapine; oral
N05AH04 [21604544]

3.0e-01

—

-1.0e+50

—

1.0e+00

1.3e+00

cases:4.44%

controls:3.34%

—

cases:0.00%

controls:0.67%

—

cases:4.51%

controls:1.69%

cases:11.76%

controls:3.52%

129

1301

—

136

1342

—

127

1279

105

1097

Differential panel, method unspecified - Blood
69738-3 [42870588]

1.8e-01

8.0e-02

—

1.3e+00

7.7e-01

cases:7.41%

controls:6.24%

cases:3.68%

controls:3.40%

—

cases:10.53%

controls:3.23%

cases:13.45%

controls:6.68%

125

1262

131

1305

—

119

1259

103

1061

Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]

6.1e-01

—

1.3e+00

cases:5.19%

controls:2.90%

—

cases:13.45%

controls:4.22%

128

1307

—

103

1089

paracetamol, combinations excl. psycholeptics
N02BE51 [21604348]

1.2e+00

—

-1.0e+50

—

cases:9.63%

controls:2.97%

—

cases:0.00%

controls:1.15%

—

122

1306

—

133

1286

—

Pneumonia, unspecified
J18.9 [45601123]

5.3e-01

—

1.2e+00

cases:4.44%

controls:2.67%

—

cases:4.51%

controls:1.46%

cases:11.76%

controls:3.78%

129

1310

—

127

1282

105

1094

Telephone prescription or other care instructions
WZB00 [2001310884]

—

-1.0e+50

—

1.2e+00

—

cases:0.00%

controls:0.96%

—

cases:10.92%

controls:3.52%

—

136

1338

—

106

1097

Medical Oncology
90 [38004507]

9.9e-01

1.2e+00

—

1.9e+00

1.4e+00

1.2e+00

cases:7.41%

controls:2.90%

cases:5.88%

controls:1.78%

—

cases:3.68%

controls:0.59%

cases:6.77%

controls:1.77%

cases:10.92%

controls:3.52%

125

1307

128

1327

—

131

1339

124

1278

106

1097

Basophils/Leukocytes in Blood
30180-4 [3022096]

-5.2e-02

-1.1e-01

—

1.3e+00

1.2e+00

7.9e-01

cases:8.15%

controls:8.54%

cases:5.15%

controls:5.70%

—

cases:3.68%

controls:1.04%

cases:12.78%

controls:4.23%

cases:21.01%

controls:10.82%

115

124

1231

129

1274

—

131

1333

116

1246

123

1014

Eosinophils/Leukocytes in Blood
26450-7 [3006504]

-6.1e-02

-1.2e-01

—

1.3e+00

1.2e+00

7.9e-01

cases:8.15%

controls:8.62%

cases:5.15%

controls:5.77%

—

cases:3.68%

controls:1.04%

cases:12.78%

controls:4.23%

cases:21.01%

controls:10.73%

116

124

1230

129

1273

—

131

1333

116

1246

122

1015

Monocytes/Leukocytes in Blood
26485-3 [3019069]

-7.1e-02

-1.1e-01

—

1.2e+00

7.9e-01

cases:8.15%

controls:8.69%

cases:5.15%

controls:5.70%

—

cases:3.68%

controls:1.11%

cases:12.78%

controls:4.23%

cases:21.01%

controls:10.73%

117

124

1229

129

1274

—

131

1332

116

1246

122

1015

Monocytes [#/volume] in Blood
26484-6 [3001604]

-3.1e-01

-7.1e-03

—

1.2e+00

7.1e-01

cases:7.41%

controls:9.81%

cases:5.88%

controls:5.92%

—

cases:3.68%

controls:1.19%

cases:14.29%

controls:4.84%

cases:21.85%

controls:12.05%

132

125

1214

128

1271

—

131

1331

114

1238

137

1000

Dyspnoea
R06.0 [45558449]

1.3e-01

7.5e-01

—

1.2e+00

cases:3.70%

controls:3.27%

cases:3.68%

controls:1.78%

—

cases:13.45%

controls:4.57%

130

1302

131

1327

—

103

1085

Basophils [#/volume] in Blood
26444-0 [3006315]

-3.2e-01

-2.0e-02

—

1.2e+00

7.2e-01

cases:7.41%

controls:9.88%

cases:5.88%

controls:6.00%

—

cases:3.68%

controls:1.19%

cases:14.29%

controls:4.92%

cases:21.85%

controls:11.96%

133

125

1213

128

1270

—

131

1331

114

1237

136

1001

Prothrombin time (PT) actual/Normal
5894-1 [3033658]

—

5.2e-01

—

1.1e+00

—

cases:3.68%

controls:2.22%

—

cases:14.29%

controls:5.01%

—

131

1321

—

102

1080

Neurology
13 [38004458]

2.2e-01

6.1e-01

—

1.1e+00

7.3e-01

cases:11.11%

controls:9.14%

cases:6.62%

controls:3.70%

—

cases:9.77%

controls:3.38%

cases:17.65%

controls:9.32%

123

120

1223

127

1301

—

120

1257

106

1031

Eosinophils [#/volume] in Blood
26449-9 [3013115]

-1.6e-01

-7.1e-03

—

1.2e+00

1.1e+00

6.0e-01

cases:8.89%

controls:10.25%

cases:5.88%

controls:5.92%

—

cases:3.68%

controls:1.19%

cases:14.29%

controls:5.23%

cases:21.85%

controls:13.28%

138

123

1208

128

1271

—

131

1331

114

1233

151

986

Oncology Clinic/Center
261QX0200X [38004268]

1.1e+00

—

6.2e-01

cases:12.59%

controls:4.61%

—

cases:7.56%

controls:4.22%

118

1284

—

110

1089

Foot/toe symptom/complaint
L17 [2002000641]

6.8e-01

—

1.1e+00

cases:6.67%

controls:3.49%

—

cases:11.76%

controls:4.31%

126

1299

—

105

1088

Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]

-2.7e-02

7.1e-02

—

7.4e-01

1.1e+00

6.3e-01

cases:10.37%

controls:10.62%

cases:7.35%

controls:6.88%

—

cases:3.68%

controls:1.78%

cases:15.79%

controls:6.07%

cases:23.53%

controls:14.07%

143

121

1203

126

1258

—

131

1323

112

1222

160

977

Bacteria [Presence] in Urine
87829-8 [36304419]

1.6e-01

4.1e-01

—

9.6e-01

1.0e+00

cases:5.19%

controls:4.46%

cases:4.41%

controls:2.96%

—

cases:6.77%

controls:2.69%

cases:15.97%

controls:6.33%

128

1286

130

1311

—

124

1266

100

1065

Casts [#/volume] in Urine by Automated count
51483-6 [3030467]

1.1e-01

4.1e-01

—

9.6e-01

1.0e+00

cases:5.19%

controls:4.68%

cases:4.41%

controls:2.96%

—

cases:6.77%

controls:2.69%

cases:16.81%

controls:6.95%

128

1283

130

1311

—

124

1266

1058

Outpatient Hospital
22 [8756]

4.2e-01

7.2e-01

-1.0e+50

—

9.8e-01

4.6e-01

cases:31.85%

controls:23.48%

cases:13.24%

controls:6.88%

cases:0.00%

controls:0.89%

—

cases:15.04%

controls:6.23%

cases:25.21%

controls:17.50%

316

1030

118

1258

136

1339

—

113

1220

199

938

Internal Medicine
11 [38004456]

4.1e-01

3.2e-01

—

1.3e+00

9.7e-01

4.4e-01

cases:25.93%

controls:18.80%

cases:11.03%

controls:8.29%

—

cases:3.68%

controls:1.04%

cases:15.79%

controls:6.61%

cases:24.37%

controls:17.24%

253

100

1093

112

121

1239

—

131

1333

112

1215

196

941

Normoblasts [#/volume] in Blood
715-3 [3021589]

6.8e-02

3.2e-01

—

1.3e+00

7.3e-01

9.4e-01

cases:8.15%

controls:7.65%

cases:8.09%

controls:6.00%

—

cases:4.41%

controls:1.26%

cases:11.28%

controls:5.76%

cases:26.05%

controls:12.05%

103

124

1243

125

1270

—

130

1330

118

1226

137

1000

Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]

5.8e-02

3.2e-01

-1.0e+50

—

8.0e-01

9.1e-01

cases:6.67%

controls:6.32%

cases:5.15%

controls:3.77%

cases:0.00%

controls:0.37%

—

cases:7.52%

controls:3.54%

cases:19.33%

controls:8.80%

126

1261

129

1300

136

1346

—

123

1255

100

1037

Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]

-1.0e-01

5.1e-01

—

7.2e-01

8.8e-01

cases:12.59%

controls:13.74%

cases:12.50%

controls:7.92%

—

cases:13.53%

controls:7.07%

cases:35.29%

controls:18.47%

185

118

1161

107

119

1244

—

115

1209

210

927

Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]

2.6e-01

5.7e-01

—

5.3e-01

8.4e-01

cases:8.15%

controls:6.39%

cases:5.88%

controls:3.40%

—

cases:6.02%

controls:3.61%

cases:20.17%

controls:9.85%

124

1260

128

1305

—

125

1254

112

1025

Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]

-3.0e-01

1.0e-01

—

7.0e-01

7.4e-01

cases:13.33%

controls:17.24%

cases:10.29%

controls:9.40%

—

cases:12.78%

controls:6.76%

cases:36.13%

controls:21.28%

232

117

1114

127

122

1224

—

116

1213

242

895

SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]

2.9e-02

5.0e-01

—

7.5e-01

4.2e-01

cases:10.37%

controls:10.10%

cases:8.82%

controls:5.55%

—

cases:9.02%

controls:4.46%

cases:20.17%

controls:14.25%

136

121

1210

124

1276

—

121

1243

162

975

Body temperature
8310-5 [3020891]

-1.0e+50

—

cases:0.00%

controls:0.37%

—

135

1341

—

Functional dyspepsia
K30 [45591584]

—

-1.0e+50

—

cases:0.00%

controls:0.37%

—

136

1346

—

Otitis externa, unspecified
H60.9 [45605727]

-1.0e+50

—

cases:0.00%

controls:0.45%

cases:0.00%

controls:0.44%

—

135

1340

136

1345

—

dexrabeprazole
A02BC07 [45893509]

—

-1.0e+50

—

cases:0.00%

controls:0.46%

—

133

1295

—

Shoulder symptom/complaint
L08 [2002000632]

—

5.9e-01

—

cases:5.88%

controls:3.34%

—

112

1099

Metal-framed partial denture
SPE02 [2001310538]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

119

1132

dextromethorphan, combinations; oral
N07XX59 [43534835]

—

-1.0e+50

—

cases:0.00%

controls:0.59%

—

136

1343

—

FEV1 --post bronchodilation
20155-8 [3023550]

—

1.8e+00

—

cases:5.88%

controls:1.06%

—

112

1125

Caries of dentine
K02.1 [45548134]

-6.3e-02

3.4e-01

—

2.2e-01

2.8e-01

cases:14.07%

controls:14.86%

cases:8.09%

controls:5.92%

—

cases:7.52%

controls:6.15%

cases:20.17%

controls:16.09%

200

116

1146

125

1271

—

123

1221

183

954

Localized oedema
R60.0 [45597193]

1.0e+00

—

cases:3.70%

controls:1.34%

—

130

1328

—

Dentistry
C5 [903277]

—

5.5e-01

—

cases:4.20%

controls:2.46%

—

114

1109

piroxicam; oral, parenteral, rectal
M01AC01 [21603961]

5.2e-01

—

3.2e-01

cases:6.67%

controls:4.09%

—

cases:4.20%

controls:3.08%

126

1291

—

114

1102

Other spondylosis with radiculopathy
M47.2 [45591850]

-1.0e+50

—

cases:0.00%

controls:0.59%

—

135

1338

—

rosuvastatin; oral
C10AA07 [21601862]

4.3e-02

6.1e-02

8.3e-01

—

1.2e-01

4.7e-01

cases:5.19%

controls:4.98%

cases:5.88%

controls:5.55%

cases:3.68%

controls:1.63%

—

cases:6.77%

controls:6.07%

cases:16.81%

controls:11.17%

128

1279

128

1276

131

1329

—

124

1222

127

1010

Osmolality of Urine
2695-5 [3026782]

2.3e-01

—

1.1e+00

1.0e+00

cases:4.44%

controls:3.57%

—

cases:4.51%

controls:1.54%

cases:10.08%

controls:3.96%

129

1298

—

127

1281

107

1092

Need for immunization against other specified single viral diseases
Z25.8 [45547296]

—

-1.0e+50

—

cases:0.00%

controls:0.89%

—

136

1339

—

ibandronic acid; oral, parenteral
M05BA06 [21604154]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

119

1132

Infiltration anesthesia
WX110 [2001310767]

-2.5e-02

1.2e-01

—

5.7e-01

2.9e-01

cases:16.30%

controls:16.64%

cases:6.62%

controls:5.92%

—

cases:9.77%

controls:5.76%

cases:21.85%

controls:17.24%

224

113

1122

127

1271

—

120

1226

196

941

Physical Medicine And Rehabilitation
25 [38004468]

1.2e-01

—

-1.0e+50

—

7.7e-01

5.2e-01

cases:7.41%

controls:6.61%

—

cases:0.00%

controls:0.37%

—

cases:3.76%

controls:1.77%

cases:10.08%

controls:6.24%

125

1257

—

136

1346

—

128

1278

107

1066

Respiratory infection other
R83 [2002000951]

3.2e-01

—

5.6e-01

cases:4.44%

controls:3.27%

—

cases:5.88%

controls:3.43%

129

1302

—

112

1098

intermediate-acting sulfonamides - combinations
J01EC20 [21602948]

—

-1.0e+50

—

cases:0.00%

controls:0.59%

—

136

1343

—

Measurement of mechanical axis of lower leg with X-ray
NJ2MA [2001308419]

—

-1.0e+50

—

cases:0.00%

controls:0.54%

—

133

1294

—

Type 2 diabetes mellitus
E11 [45571656]

-1.9e-01

6.3e-01

—

-5.3e-01

cases:4.44%

controls:5.35%

cases:3.68%

controls:2.00%

—

cases:4.20%

controls:6.95%

129

1274

131

1324

—

114

1058

Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]

-1.5e-01

5.9e-01

—

2.9e-01

cases:4.44%

controls:5.13%

cases:3.68%

controls:2.07%

—

cases:10.92%

controls:8.44%

129

1277

131

1323

—

106

1041

hydroxycarbamide; oral
L01XX05 [21603787]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.37%

cases:0.00%

controls:0.37%

—

cases:0.00%

controls:0.46%

cases:0.00%

controls:0.44%

135

1341

136

1346

—

133

1295

119

1132

Pediatric Medicine
37 [38004477]

1.0e+00

—

1.1e+00

cases:3.70%

controls:1.34%

—

cases:4.20%

controls:1.50%

130

1328

—

114

1120

Periodontal treatment by dental hygienist, very extensive
SDE04 [2001310352]

—

-1.0e+50

—

cases:0.00%

controls:0.37%

—

136

1346

—

Other extensive ultrasound examination of artery
PG1DE [2001309713]

—

-1.0e+50

—

cases:0.00%

controls:0.53%

—

119

1131

Electrophysiological examination of eye
XCD10 [2001300413]

—

1.0e+50

—

cases:3.68%

controls:0.00%

—

131

1351

—

Sinus symptom/complaint
R09 [2002000890]

—

-1.0e+50

—

cases:0.00%

controls:0.62%

—

119

1130

First degree haemorrhoids
K64.0 [45548166]

—

-1.0e+50

—

cases:0.00%

controls:0.53%

—

119

1131

duloxetine; oral
N06AX21 [21604749]

—

-1.0e+50

—

cases:0.00%

controls:0.37%

—

136

1346

—

Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma
14928-6 [3026989]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.52%

—

cases:0.00%

controls:1.23%

—

136

1344

—

119

1123

Teeth/gum disease
D82 [2002000380]

-2.2e-01

—

-1.0e+50

5.3e-01

3.9e-01

cases:5.19%

controls:6.39%

—

cases:0.00%

controls:0.59%

cases:5.26%

controls:3.15%

cases:10.92%

controls:7.65%

128

1260

—

136

1339

126

1260

106

1050

Seropositive rheumatoid arthritis, unspecified
M05.9 [45553050]

—

-1.0e+50

—

cases:0.00%

controls:0.53%

—

119

1131

Protein [Mass/volume] in Urine
2888-6 [3037121]

-1.0e+50

—

2.3e+00

cases:0.00%

controls:0.52%

—

cases:4.20%

controls:0.44%

135

1339

—

114

1132

flucloxacillin; oral, parenteral
J01CF05 [21602857]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.37%

—

cases:0.00%

controls:0.88%

—

136

1346

—

119

1127

Viral disease other/NOS
A77 [2002000211]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.37%

—

cases:0.00%

controls:0.44%

135

1341

—

119

1132

Procedure duration 10 to 19 minutes
ZXE02 [2001311396]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

136

1345

—

Urinary tract infection, site not specified
N39.0 [45548665]

1.4e+00

—

7.8e-01

cases:3.70%

controls:0.97%

—

cases:5.04%

controls:2.37%

130

1333

—

113

1110

Caries limited to enamel
K02.0 [45576967]

—

1.3e+00

—

cases:8.40%

controls:2.46%

—

109

1109

Chronic arrhythmias
207 [2001600205]

—

-1.0e+50

—

cases:0.00%

controls:0.38%

—

133

1296

—

promethazine, combinations
R06AD52 [21603489]

—

-1.0e+50

—

cases:0.00%

controls:0.59%

—

136

1343

—

Voluntary or Charitable Agency
251V00000X [38004202]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.45%

cases:0.00%

controls:0.37%

—

cases:0.00%

controls:0.70%

135

1340

136

1346

—

119

1129

Fitting of hearing aid
DAX08 [2001301529]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.37%

—

cases:0.00%

controls:0.62%

135

1341

—

119

1130

moxonidine; oral
C02AC05 [21600401]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

136

1345

—

fluvastatin; oral
C10AA04 [21601859]

—

1.2e+00

—

cases:4.20%

controls:1.32%

—

114

1122

diphenhydramine, combinations
R06AA52 [21603454]

—

-1.0e+50

—

cases:0.00%

controls:0.59%

—

136

1343

—

Tumor of uncertain or unknown nature in the ovary without histology
D39.10 [2000501354]

-1.0e+50

—

cases:0.00%

controls:0.37%

—

135

1341

—

Aortic (valve) insufficiency
I35.1 [45572087]

-1.0e+50

—

cases:0.00%

controls:0.67%

—

135

1337

—

Other disorders of vitreous body
H43.8 [45533329]

—

1.0e+50

—

cases:5.15%

controls:0.00%

—

129

1351

—

Emergency treatment
SGA01 [2001310379]

—

4.8e-01

—

cases:4.20%

controls:2.64%

—

114

1107

combinations of xanthines
R03DA20 [21603340]

-1.0e+50

—

cases:0.00%

controls:0.37%

—

135

1341

—

proguanil and atovaquone
P01BB51 [21604895]

—

-1.0e+50

—

cases:0.00%

controls:0.53%

—

119

1131

Cardiodefibrillation
TFP20 [2001303224]

—

-1.0e+50

—

cases:0.00%

controls:0.70%

—

119

1129

Examination for driving licence
Z02.4 [45552056]

-1.0e+50

—

4.4e-02

cases:0.00%

controls:4.09%

—

cases:5.04%

controls:4.84%

135

1291

—

113

1082

betamethasone
S02BA07 [21605169]

1.9e-02

—

-1.0e+50

—

4.6e-01

cases:7.41%

controls:7.28%

—

cases:0.00%

controls:0.45%

—

cases:10.08%

controls:6.60%

125

1248

—

136

1341

—

107

1062

folic acid; oral, parenteral
B03BB01 [21601129]

-1.0e+50

—

cases:0.00%

controls:1.04%

—

135

1332

—

Assessment of need for services (elderly/care support)
SPAT1217 [2001700318]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.89%

—

cases:0.00%

controls:1.06%

135

1334

—

119

1125

ketotifen
S01GX08 [21605092]

—

-1.0e+50

—

cases:0.00%

controls:0.88%

—

119

1127

isosorbide mononitrate; oral
C01DA14 [21600324]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:2.22%

cases:0.00%

controls:0.89%

—

cases:0.00%

controls:0.52%

cases:0.00%

controls:2.31%

cases:0.00%

controls:3.96%

—

136

1321

136

1339

—

136

1340

133

1271

119

1092

miconazole
D01AC02 [21601921]

-1.0e+50

—

cases:0.00%

controls:1.34%

cases:0.00%

controls:0.37%

—

135

1328

136

1346

—

olanzapine; oral, parenteral
N05AH03 [21604543]

—

-1.0e+50

—

cases:0.00%

controls:0.45%

—

136

1341

—

insulin detemir; parenteral
A10AE05 [21600740]

—

-1.0e+50

—

cases:0.00%

controls:0.37%

—

136

1346

—

nilvadipine; oral
C08CA10 [21601756]

-1.0e+50

—

cases:0.00%

controls:0.45%

—

135

1340

—

Necrosis of pulp
K04.1 [45572186]

-1.0e+50

—

cases:0.00%

controls:1.04%

—

135

1332

—

Oral and dental health check by dental hygienist or dental assistant
SAB02 [2001310280]

-1.0e+50

—

cases:0.00%

controls:0.52%

—

135

1339

—

dydrogesterone; oral
G03DB01 [21602544]

—

-1.0e+50

—

cases:0.00%

controls:0.38%

—

133

1296

—

tenoxicam; oral, parenteral, rectal
M01AC02 [21603962]

-1.0e+50

—

cases:0.00%

controls:0.45%

—

135

1340

—

Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]

-5.8e-02

2.6e-01

—

8.1e-01

2.4e-01

4.0e-01

cases:22.96%

controls:24.00%

cases:18.38%

controls:14.80%

—

cases:4.41%

controls:2.00%

cases:16.54%

controls:13.45%

cases:42.86%

controls:33.51%

323

104

1023

200

111

1151

—

130

1320

175

111

1126

381

756

Observation for other suspected diseases and conditions
Z03.80 [2000503756]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

119

1132

Diabetes, insulin-treated
103 [2001600103]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

cases:0.00%

controls:0.38%

—

136

1345

—

133

1296

—

Tissue Pathology biopsy report
66121-5 [40768804]

-2.0e-01

8.5e-01

—

4.8e-01

cases:6.67%

controls:8.02%

cases:5.88%

controls:2.59%

—

cases:10.08%

controls:6.51%

108

126

1238

128

1316

—

107

1063

Acute stress reaction
P02 [2002000799]

—

-1.0e+50

—

cases:0.00%

controls:0.70%

—

119

1129

norethisterone; oral
G03DC02 [21602553]

—

-1.0e+50

—

cases:0.00%

controls:0.52%

—

136

1344

—

Hematology
82 [38004501]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.74%

cases:0.00%

controls:0.59%

—

cases:0.00%

controls:0.69%

—

135

1336

136

1343

—

133

1292

—

Cystoscopy
UKC02 [2001306005]

—

1.1e+00

—

cases:3.76%

controls:1.23%

—

128

1285

—

Spirometry study
18759-1 [3000492]

—

1.5e+00

—

cases:5.04%

controls:1.14%

—

113

1124

pneumococcus, purified polysaccharides antigen conjugated
J07AL02 [21601313]

-1.0e+50

—

cases:0.00%

controls:1.93%

—

135

1320

—

Acute bronchitis, unspecified
J20.9 [45562445]

8.4e-01

—

5.5e-01

cases:5.19%

controls:2.30%

—

cases:4.20%

controls:2.46%

128

1315

—

114

1109

pantoprazole; oral, parenteral
A02BC02 [21600097]

-2.6e-01

—

-2.2e-01

1.7e-01

cases:14.07%

controls:17.46%

cases:8.82%

controls:11.10%

—

cases:8.27%

controls:10.07%

cases:23.53%

controls:20.67%

235

116

1111

150

124

1201

—

131

122

1170

235

902

acetylsalicylic acid; oral
B01AC06 [21600991]

4.6e-01

—

6.9e-01

2.9e-01

cases:3.70%

controls:2.38%

—

cases:3.76%

controls:1.92%

cases:4.20%

controls:3.17%

130

1314

—

128

1276

114

1101

celecoxib
L01XX33 [21603805]

—

-1.0e+50

—

cases:0.00%

controls:0.59%

—

136

1343

—

Hand Surgery
40 [38004480]

—

-1.0e+50

—

8.6e-01

—

cases:0.00%

controls:0.45%

—

cases:5.04%

controls:2.20%

—

136

1341

—

113

1112

glucosamine; oral
M01AX05 [21604002]

3.9e-01

—

-1.0e+50

—

cases:5.93%

controls:4.09%

—

cases:0.00%

controls:1.31%

—

127

1291

—

133

1284

—

dexamethasone and antiinfectives
S02CA06 [21605178]

—

-1.0e+50

—

cases:0.00%

controls:0.46%

—

133

1295

—

Upper gastrointestinal surgery
106 [44777669]

1.7e-01

4.9e-01

-1.0e+50

—

7.4e-01

cases:9.63%

controls:8.25%

cases:5.88%

controls:3.70%

cases:0.00%

controls:0.59%

—

cases:17.65%

controls:9.23%

111

122

1235

128

1301

136

1343

—

105

1032

insulin (human); parenteral
A10AB01 [21600715]

—

-1.0e+50

—

cases:0.00%

controls:0.70%

—

119

1129

Alzheimer disease, unspecified
G30.9 [45591165]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

119

1132

Fetal Trisomy 21 risk [Likelihood] Based on maternal age
49090-4 [3049207]

—

-1.0e+50

—

cases:0.00%

controls:0.37%

—

136

1346

—

Low back pain
M54.5 [45553207]

-5.4e-01

-1.0e+50

—

-1.0e+50

3.2e-01

cases:3.70%

controls:6.17%

cases:0.00%

controls:2.15%

—

cases:0.00%

controls:1.77%

cases:7.56%

controls:5.63%

130

1263

136

1322

—

133

1278

110

1073

Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]

1.2e-01

-7.5e-02

—

-2.3e-02

2.5e-01

cases:8.15%

controls:7.28%

cases:4.41%

controls:4.74%

—

cases:5.26%

controls:5.38%

cases:13.45%

controls:10.82%

124

1248

130

1287

—

126

1231

123

103

1014

orphenadrine, combinations
M03BC51 [21604113]

1.1e+00

—

-1.0e+50

—

cases:8.15%

controls:2.75%

—

cases:0.00%

controls:1.15%

—

124

1309

—

133

1286

—

Assessment of need for rehabilitation and/or rehabilitation plan
SPAT1220 [2001700321]

-1.0e+50

—

cases:0.00%

controls:1.11%

—

135

1331

—

Spirometry at the office
SPAT1059 [2001700160]

-1.0e+50

—

cases:0.00%

controls:0.45%

—

135

1340

—

Clinic/Center
261Q00000X [38004207]

-1.0e+50

—

cases:0.00%

controls:0.74%

—

135

1336

—

Animal/human bite
S13 [2002000978]

-1.0e+50

—

cases:0.00%

controls:0.37%

—

135

1341

—

Sciatica
M54.3 [45586994]

—

-1.0e+50

—

cases:0.00%

controls:0.70%

—

119

1129

Screening of depression or other psychiatric problem
SPAT1246 [2001700347]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

119

1132

Periodontal treatment, very brief
SDA01 [2001310326]

1.6e-01

—

cases:5.19%

controls:4.46%

—

128

1286

—

scopolamine, combinations
A04AD51 [21600507]

—

-1.0e+50

—

cases:0.00%

controls:0.79%

—

119

1128

Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]

-1.1e-01

3.4e-01

6.8e-01

—

1.1e+00

3.2e-01

cases:27.41%

controls:29.57%

cases:29.41%

controls:22.80%

cases:6.62%

controls:3.48%

—

cases:8.09%

controls:2.97%

cases:28.57%

controls:22.44%

cases:51.26%

controls:43.18%

398

948

308

1043

127

1304

—

125

1307

292

1009

491

646

Conjunctivitis, unspecified
H10.9 [45591253]

-1.0e+50

—

cases:0.00%

controls:0.37%

—

135

1341

—

Pain localized to other parts of lower abdomen
R10.3 [45534426]

—

-1.0e+50

—

8.8e-01

—

cases:0.00%

controls:0.67%

—

cases:6.72%

controls:2.90%

—

136

1342

—

111

1104

Bicarbonate [Moles/volume] in Venous blood
14627-4 [3027273]

—

-1.0e+50

—

cases:0.00%

controls:1.23%

—

119

1123

Leg/thigh symptom/complaint
L14 [2002000638]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.89%

—

cases:0.00%

controls:0.70%

135

1334

—

119

1129

Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]

—

-1.0e+50

1.1e+00

—

cases:0.00%

controls:0.69%

cases:5.04%

controls:1.76%

—

133

1292

113

1117

clindamycin
D10AF01 [21602305]

-1.0e+50

—

cases:0.00%

controls:0.52%

—

135

1339

—

fluticasone furoate; nasal
R01AD12 [21605053]

-2.3e-01

-2.0e-01

—

-1.0e+50

4.9e-01

7.9e-01

cases:8.15%

controls:10.03%

cases:3.68%

controls:4.44%

—

cases:0.00%

controls:1.04%

cases:6.02%

controls:3.77%

cases:15.97%

controls:7.92%

135

124

1211

131

1291

—

136

1333

125

1252

100

1047

pH of Capillary blood
2745-8 [3009343]

-1.0e+50

—

cases:0.00%

controls:1.11%

—

135

1331

—

sertraline; oral
N06AB06 [21604714]

—

8.9e-01

—

cases:4.20%

controls:1.76%

—

114

1117

Urology
34 [38004474]

6.7e-01

8.0e-01

—

3.7e-01

2.9e-01

cases:8.89%

controls:4.75%

cases:5.15%

controls:2.37%

—

cases:6.02%

controls:4.23%

cases:8.40%

controls:6.42%

123

1282

129

1319

—

125

1246

109

1064

estradiol; nasal, oral, parenteral, rectal, transdermal, vaginal
G03CA03 [21602517]

1.9e-01

3.5e-01

2.2e-01

—

3.6e-01

3.3e-01

3.1e-01

cases:20.74%

controls:17.76%

cases:17.65%

controls:13.18%

cases:3.68%

controls:2.96%

—

cases:3.68%

controls:2.60%

cases:15.79%

controls:11.91%

cases:24.37%

controls:19.09%

239

107

1107

178

112

1173

131

1311

—

131

1312

155

112

1146

217

920

Mental and behavioural disorders due to use of alcohol, Harmful use
F10.1 [45595844]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.74%

—

cases:0.00%

controls:0.70%

135

1336

—

119

1129

Cancer Ag 125 [Units/volume] in Serum or Plasma
10334-1 [3037551]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

136

1345

—

Laceration/cut
S18 [2002000983]

-3.3e-01

—

5.6e-01

cases:5.93%

controls:8.02%

—

cases:14.29%

controls:8.71%

108

127

1238

—

102

1038

Prostate Pathology biopsy report
66117-3 [40768800]

—

-1.0e+50

—

cases:0.00%

controls:0.52%

—

136

1344

—

fluticasone; nasal
R01AD08 [21605050]

-2.3e-01

-2.0e-01

—

-1.0e+50

4.9e-01

7.9e-01

cases:8.15%

controls:10.03%

cases:3.68%

controls:4.44%

—

cases:0.00%

controls:1.04%

cases:6.02%

controls:3.77%

cases:15.97%

controls:7.92%

135

124

1211

131

1291

—

136

1333

125

1252

100

1047

Dental impressions
SBB10 [2001310299]

-1.0e+50

—

cases:0.00%

controls:0.52%

—

135

1339

—

desloratadine; oral
R06AX27 [21603526]

-1.6e-01

—

-1.0e+50

—

8.6e-02

3.5e-01

cases:5.19%

controls:6.02%

—

cases:0.00%

controls:0.52%

—

cases:3.76%

controls:3.46%

cases:8.40%

controls:6.07%

128

1265

—

136

1344

—

128

1256

109

1068

Preparing and fitting the occlusal splint in the mouth
SHB00 [2001310410]

—

-1.0e+50

—

cases:0.00%

controls:0.46%

cases:0.00%

controls:1.14%

—

133

1295

119

1124

dexamethasone and antiinfectives
S03CA01 [21605206]

—

-1.0e+50

—

cases:0.00%

controls:0.77%

—

133

1291

—

Periapical abscess without sinus
K04.7 [45586692]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

119

1132

Thyrotropin receptor Ab [Units/volume] in Serum
5385-0 [3017044]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

119

1132

oxybutynin; oral, transdermal
G04BD04 [21602637]

-1.0e+50

—

cases:0.00%

controls:0.82%

—

135

1335

—

Breast Pathology biopsy report
66110-8 [40768793]

-1.0e+50

—

cases:0.00%

controls:0.37%

—

135

1341

—

Emergency Room and Inpatient Visit
ERIP [262]

—

6.4e-01

—

cases:15.13%

controls:8.62%

—

101

1039

Treponema pallidum Ab [Presence] in Serum
22587-0 [3019832]

—

1.3e+00

—

cases:5.04%

controls:1.50%

—

113

1120

Angiography of heart and/or coronary arteries
FN1AC [2001302996]

—

-1.0e+50

3.8e-01

—

cases:0.00%

controls:0.92%

cases:4.20%

controls:2.90%

—

133

1289

114

1104

Demanding operative extraction of tooth
EBA12 [2001301926]

—

-1.0e+50

—

cases:0.00%

controls:0.53%

—

119

1131

Pain in joint
M25.5 [45586941]

6.7e-01

—

8.4e-01

cases:7.41%

controls:3.94%

—

cases:10.92%

controls:5.01%

125

1293

—

106

1080

Cholesterol non HDL [Moles/volume] in Serum or Plasma
70204-3 [42868678]

-1.0e+50

—

cases:0.00%

controls:0.59%

cases:0.00%

controls:0.59%

—

135

1338

136

1343

—

Health check-up of pregnant person
SPAT1379 [2001700479]

—

-1.0e+50

—

cases:0.00%

controls:0.79%

—

119

1128

Vomiting
D10 [2002000309]

-1.0e+50

—

cases:0.00%

controls:0.45%

—

135

1340

—

Presbycusis
H91.1 [45591444]

—

-1.0e+50

—

cases:0.00%

controls:0.46%

—

133

1295

—

Extensive CT of neck arteries
PA6BD [2001308697]

-1.0e+50

—

cases:0.00%

controls:0.52%

—

135

1339

—

Right side
ZXA00 [2001311346]

7.9e-01

—

1.3e+00

4.1e-01

cases:7.41%

controls:3.49%

—

cases:3.76%

controls:1.08%

cases:4.20%

controls:2.81%

125

1299

—

128

1287

114

1105

levocetirizine; oral
R06AE09 [21603498]

—

-1.0e+50

—

cases:0.00%

controls:0.37%

—

136

1346

—

olaflur; oral
A01AA03 [21600007]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

119

1132

Other specified urinary incontinence
N39.4 [45577525]

-1.0e+50

—

cases:0.00%

controls:0.74%

cases:0.00%

controls:0.37%

—

135

1336

136

1346

—

Patch test
41778007 [4218642]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.67%

—

cases:0.00%

controls:0.53%

135

1337

—

119

1131

Application of soft bandage
SPAT1211 [2001700312]

—

-1.0e+50

—

cases:0.00%

controls:0.67%

—

136

1342

—

Thorax X-ray examination outside radiological department
GD1UA [2001303652]

—

1.1e+00

—

cases:4.20%

controls:1.50%

—

114

1120

Treatment of reopened or infected surgical wound
SPAT1144 [2001700245]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.45%

—

cases:0.00%

controls:0.97%

135

1340

—

119

1126

Complement C3 [Mass/volume] in Serum or Plasma
4485-9 [3000620]

-1.0e+50

—

cases:0.00%

controls:0.52%

cases:0.00%

controls:0.37%

—

135

1339

136

1346

—

Internal hemorrhoids without complication
I84.2 [45596267]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

119

1132

Myelocytes/Leukocytes in Blood
26498-6 [3017181]

-1.0e+50

—

7.5e-01

cases:0.00%

controls:0.74%

—

cases:4.20%

controls:2.02%

135

1336

—

114

1114

Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]

—

-1.0e+50

—

cases:0.00%

controls:0.46%

—

133

1295

—

Monitoring the use of the aid
R5140 [2001310249]

—

1.5e+00

—

cases:5.88%

controls:1.32%

—

112

1122

Chorioretinal scars
H31.0 [45543017]

—

1.0e+50

—

cases:97.06%

controls:0.00%

cases:13.24%

controls:0.00%

cases:22.56%

controls:0.00%

cases:15.13%

controls:0.00%

—

132

1351

118

1347

103

1301

101

1137

phenoxymethylpenicillin; oral
J01CE02 [21602842]

9.4e-02

—

4.7e-01

cases:14.81%

controls:13.67%

—

cases:16.81%

controls:11.17%

184

115

1162

—

127

1010

Provision of consultation response
SPAT1285 [2001700386]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.52%

cases:0.00%

controls:0.37%

—

cases:0.00%

controls:0.53%

135

1339

136

1346

—

119

1131

phenylephrine, combinations
R01BA53 [21603214]

5.2e-01

—

cases:3.70%

controls:2.23%

—

130

1316

—

Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]

—

-1.0e+50

—

cases:0.00%

controls:0.69%

—

133

1292

—

Postmenopausal atrophic vaginitis
N95.2 [45582430]

-1.0e+50

—

cases:0.00%

controls:0.67%

—

135

1337

—

Complicated extraction of tooth
EBA05 [2001301924]

5.9e-01

—

-1.0e+50

4.6e-01

cases:3.70%

controls:2.08%

—

cases:0.00%

controls:1.00%

cases:5.04%

controls:3.25%

130

1318

—

133

1288

113

1100

clindamycin; oral, parenteral
J01FF01 [21602985]

1.1e+00

—

1.2e+00

cases:7.41%

controls:2.67%

—

cases:5.88%

controls:1.93%

125

1310

—

112

1115

Periodontal treatment by dental hygienist, extensive
SDE03 [2001310351]

1.5e-01

1.8e+00

—

-1.0e+50

7.1e-01

cases:3.70%

controls:3.19%

cases:4.41%

controls:0.74%

—

cases:0.00%

controls:0.77%

cases:4.20%

controls:2.11%

130

1303

130

1341

—

133

1291

114

1113

INR in Blood by Coagulation assay
34714-6 [3032080]

-4.4e-01

-1.2e-01

—

5.9e-01

5.8e-01

cases:5.93%

controls:8.92%

cases:4.41%

controls:4.96%

—

cases:8.27%

controls:4.77%

cases:19.33%

controls:11.87%

120

127

1226

130

1284

—

122

1239

135

1002

Pelvis X-ray examination
NE1AA [2001307792]

-1.0e+50

—

cases:0.00%

controls:0.52%

cases:0.00%

controls:0.44%

—

135

1339

136

1345

—

Cutaneous abscess, furuncle and carbuncle of limb
L02.4 [45552967]

-1.0e+50

—

cases:0.00%

controls:0.45%

—

135

1340

—

Midwife
Z3232 [2001311563]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.82%

—

cases:0.00%

controls:0.44%

135

1335

—

119

1132

tizanidine; oral
M03BX02 [21604116]

-8.2e-02

—

-1.0e+50

—

6.8e-02

2.7e-02

cases:12.59%

controls:13.52%

—

cases:0.00%

controls:0.44%

—

cases:4.51%

controls:4.23%

cases:12.61%

controls:12.31%

182

118

1164

—

136

1345

—

127

1246

140

104

997

Day surgery
ZXD20 [2001311388]

—

-1.0e+50

—

cases:0.00%

controls:0.59%

—

136

1343

—

Atherosclerotic cardiovascular disease, so described
I25.0 [45552783]

-1.0e+50

—

cases:0.00%

controls:0.37%

—

135

1341

—

ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]

4.7e-01

—

6.8e-01

cases:8.15%

controls:5.27%

—

cases:5.88%

controls:3.08%

124

1275

—

112

1102

leuprorelin; implant, parenteral
L02AE02 [21603825]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

119

1132

Chronic ulcer skin
S97 [2002001061]

-1.0e+50

—

cases:0.00%

controls:0.52%

—

135

1339

—

Glucose [Moles/volume] in Venous blood
39480-9 [3038515]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

119

1132

Gastro-oesophageal reflux disease
K21 [45586708]

—

-1.0e+50

—

cases:0.00%

controls:0.79%

—

119

1128

Urinary calculus, unspecified
N20.9 [45558141]

-1.0e+50

—

cases:0.00%

controls:0.52%

—

135

1339

—

HLA-B27 [Presence]
4821-5 [3008898]

—

-1.0e+50

—

cases:0.00%

controls:0.62%

—

119

1130

Sialoadenitis
K11.2 [45586705]

—

-1.0e+50

—

cases:0.00%

controls:0.53%

—

119

1131

Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]

—

1.3e+00

—

cases:5.04%

controls:1.41%

—

113

1121

Norovirus RNA [Presence] in Stool by NAA with probe detection
7974-9 [3008909]

—

-1.0e+50

—

cases:0.00%

controls:0.53%

—

119

1131

hydrocortisone
D07AA02 [21602102]

-2.8e-01

—

2.3e-01

cases:5.93%

controls:7.73%

—

cases:8.40%

controls:6.77%

104

127

1242

—

109

1060

insulin lispro; parenteral
A10AD04 [21600732]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.67%

cases:0.00%

controls:0.59%

—

cases:0.00%

controls:0.46%

cases:0.00%

controls:0.44%

135

1337

136

1343

—

133

1295

119

1132

Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]

-1.7e-01

4.4e-01

—

7.5e-01

cases:7.41%

controls:8.69%

cases:7.35%

controls:4.89%

—

cases:9.02%

controls:4.46%

cases:24.37%

controls:13.19%

117

125

1229

126

1285

—

121

1243

150

987

Lateral epicondylitis
M77.1 [45572551]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.52%

—

cases:0.00%

controls:0.44%

—

136

1344

—

119

1132

General medical examination
Z00.0 [45585791]

—

9.8e-01

—

cases:5.88%

controls:2.29%

—

112

1111

bisoprolol; oral
C07AB07 [21601689]

1.6e-01

3.5e-01

2.5e-01

—

-2.7e-02

4.3e-01

4.7e-01

cases:17.04%

controls:14.86%

cases:17.65%

controls:13.10%

cases:4.41%

controls:3.48%

—

cases:4.41%

controls:4.53%

cases:19.55%

controls:13.68%

cases:26.05%

controls:18.03%

200

112

1146

177

112

1174

130

1304

—

130

1286

178

107

1123

205

932

Other and unspecified ovarian cysts
N83.2 [45539066]

-1.0e+50

—

cases:0.00%

controls:1.34%

—

135

1328

—

folic acid
V04CX02 [715877]

-1.0e+50

—

cases:0.00%

controls:1.04%

—

135

1332

—

plastic IUD with progestogen; implant
G02BA03 [21602449]

—

-1.0e+50

—

cases:0.00%

controls:0.52%

—

136

1344

—

Hospital outpatient
ZY010 [2001311599]

—

-1.0e+50

—

cases:0.00%

controls:0.38%

cases:0.00%

controls:0.44%

—

133

1296

119

1132

Abdominal CT examination both without and with contrast
JN3CD [2001305561]

-1.0e+50

—

cases:0.00%

controls:0.45%

—

135

1340

—

Glucose [Moles/volume] in Serum or Plasma --2 hours post meal
14761-1 [3012413]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

119

1132

Gingivitis (chronic) NOS
K05.10 [2000502717]

—

-1.0e+50

1.2e+00

—

cases:0.00%

controls:0.77%

cases:5.04%

controls:1.58%

—

133

1291

113

1119

Physiotherapy
R4110 [2001310233]

5.9e-01

—

9.2e-01

cases:6.67%

controls:3.79%

—

cases:8.40%

controls:3.52%

126

1295

—

109

1097

Hemorrhoids
I84 [45586644]

-1.0e+50

—

cases:0.00%

controls:0.37%

—

135

1341

—

nebivolol; oral
C07AB12 [21601694]

—

-1.0e+50

—

cases:0.00%

controls:0.62%

—

119

1130

zopiclone; oral
N05CF01 [21604654]

5.6e-01

7.3e-01

—

4.2e-01

7.4e-01

cases:11.11%

controls:6.69%

cases:8.82%

controls:4.44%

—

cases:6.77%

controls:4.53%

cases:12.61%

controls:6.42%

120

1256

124

1291

—

124

1242

104

1064

Periodontitis pronounced
K05.31 [2000502729]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.56%

cases:0.00%

controls:0.44%

—

cases:0.00%

controls:0.46%

—

135

1325

136

1345

—

133

1295

—

Palpitations
R00.2 [45558446]

—

-1.0e+50

—

cases:0.00%

controls:0.46%

cases:0.00%

controls:0.88%

—

133

1295

119

1127

formoterol and budesonide
R03AK07 [21603281]

—

-1.0e+50

—

cases:0.00%

controls:0.59%

—

136

1343

—

Recording of ECG
SPAT1097 [2001700198]

6.3e-01

-1.0e+50

—

cases:3.70%

controls:2.01%

cases:0.00%

controls:0.89%

—

130

1319

136

1339

—

Kappa light chains.free [Mass/volume] in Serum
36916-5 [3034860]

—

-1.0e+50

—

cases:0.00%

controls:0.46%

—

133

1295

—

chlorhexidine
S03AA04 [21605193]

—

-1.0e+50

—

9.5e-01

—

cases:0.00%

controls:0.89%

—

cases:4.20%

controls:1.67%

—

136

1339

—

114

1118

Respiratory disease other
R99 [2002000964]

-1.0e+50

—

cases:0.00%

controls:0.37%

—

135

1341

—

Leukocytes [Presence] in Urine
33052-2 [3045414]

-1.0e+50

—

cases:0.00%

controls:0.37%

cases:0.00%

controls:0.67%

—

135

1341

136

1342

—

Blepharitis
H01.0 [45533180]

—

-1.0e+50

—

cases:0.00%

controls:0.79%

—

119

1128

Carotid artery syndrome (hemispheric)
G45.1 [45576586]

-1.0e+50

—

cases:0.00%

controls:0.37%

—

135

1341

—

Observation for suspected disease or condition, unspecified
Z03.9 [45552062]

3.6e-01

—

6.8e-01

cases:3.70%

controls:2.60%

—

cases:5.88%

controls:3.08%

130

1311

—

112

1102

Benign neoplasm: Stomach
D13.1 [45586087]

-1.0e+50

—

cases:0.00%

controls:0.52%

—

135

1339

—

Type 2 diabetes mellitus, with unspecified complications
E11.8 [45561951]

-1.0e+50

—

cases:0.00%

controls:0.82%

cases:0.00%

controls:0.59%

—

135

1335

136

1343

—

Other function in accordance with SHToL (Finnish classification of nursing interventions)
SPAT1292 [2001700393]

-1.0e+50

—

cases:0.00%

controls:1.71%

cases:0.00%

controls:0.74%

—

135

1323

136

1341

—

Physiotherapist
Z3226 [2001311560]

1.3e+00

—

1.4e+00

cases:5.93%

controls:1.71%

—

cases:5.88%

controls:1.50%

127

1323

—

112

1120

Asthma, unspecified
J45.9 [45562456]

—

1.2e+00

8.1e-01

—

cases:6.02%

controls:1.84%

cases:7.56%

controls:3.52%

—

125

1277

110

1097

Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]

-1.0e+50

—

-1.0e+50

—

6.7e-01

cases:0.00%

controls:4.61%

—

cases:0.00%

controls:0.37%

—

cases:15.13%

controls:8.36%

135

1284

—

136

1346

—

101

1042

losartan; oral
C09CA01 [21601824]

3.7e-01

-1.4e-01

—

1.2e-02

5.2e-01

cases:6.67%

controls:4.68%

cases:3.68%

controls:4.22%

—

cases:4.51%

controls:4.46%

cases:9.24%

controls:5.72%

126

1283

131

1294

—

127

1243

108

1072

SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]

—

-1.0e+50

—

cases:0.00%

controls:0.37%

—

136

1346

—

colestyramine; oral
C10AC01 [21601876]

-1.0e+50

—

cases:0.00%

controls:0.37%

—

135

1341

—

nedocromil; inhalant
R03BC03 [21603299]

—

-1.0e+50

—

cases:0.00%

controls:0.53%

—

119

1131

Resting ECG, 12 leads
FP1B5 [2001303119]

—

-1.0e+50

—

cases:0.00%

controls:0.53%

—

119

1131

Photography of fundus of eye
XCK10 [2001301381]

1.9e+00

—

1.0e+50

—

1.5e+00

cases:4.44%

controls:0.67%

—

cases:7.35%

controls:0.00%

—

cases:4.20%

controls:0.97%

129

1337

—

126

1351

—

114

1126

cetirizine; oral
R06AE07 [21603497]

1.0e-01

1.7e-01

-1.0e+50

—

3.4e-01

cases:9.63%

controls:8.77%

cases:3.68%

controls:3.11%

cases:0.00%

controls:0.44%

—

cases:10.92%

controls:8.00%

118

122

1228

131

1309

136

1345

—

106

1046

Emergency visit or other similar visit involving procedures
WYA05 [2001310871]

2.9e-01

—

1.2e-01

cases:10.37%

controls:7.95%

—

cases:7.56%

controls:6.77%

107

121

1239

—

110

1060

Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]

—

-1.0e+50

—

1.2e+00

—

cases:0.00%

controls:0.37%

—

cases:5.88%

controls:1.85%

—

136

1346

—

112

1116

Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]

-4.9e-01

5.5e-01

-1.0e+50

—

8.4e-01

4.1e-01

cases:4.44%

controls:7.06%

cases:5.88%

controls:3.48%

cases:0.00%

controls:0.44%

—

cases:6.02%

controls:2.69%

cases:14.29%

controls:9.94%

129

1251

128

1304

136

1345

—

125

1266

113

102

1024

Health maint/preventive medicine
A98 [2002000231]

1.0e-01

3.2e-01

—

7.7e-01

3.5e-01

3.4e-01

cases:35.56%

controls:33.21%

cases:33.09%

controls:26.35%

—

cases:10.29%

controls:5.05%

cases:35.34%

controls:27.90%

cases:57.98%

controls:49.52%

447

899

356

995

—

122

1279

363

938

563

574

FEV1
20150-9 [3024653]

—

1.7e+00

—

cases:5.88%

controls:1.14%

—

112

1124

Contusion of shoulder and upper arm
S40.0 [45563774]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

119

1132

Obesity
E66 [45547648]

—

-1.0e+50

—

cases:0.00%

controls:0.62%

—

119

1130

Essential (primary) hypertension
I10 [45591453]

1.9e-01

5.7e-01

—

8.3e-02

2.5e-01

cases:20.74%

controls:17.76%

cases:15.44%

controls:9.33%

—

cases:9.77%

controls:9.07%

cases:26.89%

controls:22.25%

239

107

1107

126

115

1225

—

118

120

1183

253

884

metoprolol; oral, parenteral
C07AB02 [21601684]

-7.6e-02

3.9e-02

—

3.9e-02

5.2e-01

cases:5.19%

controls:5.57%

cases:5.15%

controls:4.96%

—

cases:5.26%

controls:5.07%

cases:9.24%

controls:5.72%

128

1271

129

1284

—

126

1235

108

1072

Endoscopic polypectomy in colon
JFA15 [2001304850]

-1.0e+50

—

cases:0.00%

controls:0.45%

—

135

1340

—

Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]

—

1.7e+00

7.1e-01

—

cases:5.26%

controls:1.00%

cases:4.20%

controls:2.11%

—

126

1288

114

1113

filgrastim; parenteral
L03AA02 [21603851]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

119

1132

Open wound on lip
S01.51 [2000503614]

—

-1.0e+50

—

cases:0.00%

controls:0.44%

—

119

1132

diclofenac; ointment
M02AA15 [21604051]

9.9e-01

—

-1.0e+50

—

1.3e+00

cases:7.41%

controls:2.90%

—

cases:0.00%

controls:0.37%

—

cases:7.56%

controls:2.20%

125

1307

—

136

1342

—

110

1112

betahistine; oral
N07CA01 [21604833]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.97%

—

cases:0.00%

controls:0.46%

—

135

1333

—

133

1295

—

Three-surface restoration
SFA30 [2001310360]

2.3e-01

—

7.7e-01

1.8e-01

cases:9.63%

controls:7.80%

—

cases:3.76%

controls:1.77%

cases:10.92%

controls:9.32%

105

122

1241

—

128

1278

106

1031

Gynaecological examination (general)(routine)
Z01.4 [45542395]

—

-1.0e+50

—

cases:0.00%

controls:0.67%

—

136

1342

—

Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]

2.3e-01

1.2e-01

6.3e-01

—

7.6e-01

3.5e-01

3.9e-01

cases:25.93%

controls:21.77%

cases:19.85%

controls:18.06%

cases:5.15%

controls:2.81%

—

cases:6.62%

controls:3.19%

cases:24.06%

controls:18.29%

cases:46.22%

controls:36.85%

293

100

1053

244

109

1107

129

1313

—

127

1304

238

101

1063

419

718

combinations of corticosteroids
D07XB30 [21602188]

-2.6e-01

—

1.2e-02

5.4e-01

cases:8.89%

controls:11.22%

—

cases:4.51%

controls:4.46%

cases:17.65%

controls:11.08%

151

123

1195

—

127

1243

126

1011

Ultrasound examination of lower leg veins
PH2AE [2001309451]

—

-1.0e+50

—

cases:0.00%

controls:1.06%

—

119

1125

SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay
96119-3 [36032419]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.59%

—

cases:0.00%

controls:0.70%

135

1338

—

119

1129

LabWAS

↥

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(3026493) Urate [Moles/volume] in Serum or Plasma

332

2.16

4.46

3.8

2.9

338.84

340.51

umol/l

0.05

293

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

3.31

3.94

1.5

1.7

—

(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count

221

2.07

3.37

3.2

3.1

1.21

0.95

e6/l

0.12

106

(3002582) Erythrocytes [#/volume] in Urine

417

1.88

3.25

4.6

3.4

95.16

207.52

e6/l

0.28

313

(3051714) Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma

272

1.97

3.24

2.8

2.0

1.03

1.46

mg/l

0.65

217

(3030467) Casts [#/volume] in Urine by Automated count

359

1.88

3.14

3.9

3.3

0.17

0.52

e6/l

1.38

256

(3015736) pH of Urine

529

1.81

2.93

4.7

3.6

6.32

6.25

0.18

289

(3014051) Protein [Presence] in Urine by Test strip

366

1.84

2.92

4.2

3.0

—

0.20

—

(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells

3.32

2.71

1.3

1.9

—

(3021589) Normoblasts [#/volume] in Blood

567

1.76

2.68

19.7

12.1

0.00

e9/l

0.72

455

(3018095) Leukocytes [#/volume] in Urine

480

1.72

2.50

5.8

4.1

34.05

99.81

e6/l

1.06

325

(42870588) Differential panel, method unspecified - Blood

418

1.72

2.44

8.6

7.0

—

(3012220) Varicella zoster virus IgM Ab [Presence] in Serum by Immunoassay

5.17

2.43

1.2

1.1

—

(3014148) Varicella zoster virus Ab [Titer] in Serum

5.17

2.43

1.2

1.1

—

(40758895) Direct antiglobulin test.complement C3d specific reagent [Presence] on Red Blood Cells

6.43

2.39

1.6

3.4

—

(40758897) Direct antiglobulin test.IgG specific reagent [Presence] on Red Blood Cells

6.43

2.39

1.6

3.4

—

(36305247) Microscopic observation [Identifier] in Isolate by Gram stain

3.09

2.33

1.8

1.5

—

(3018418) pH of Serum or Plasma

396

1.70

2.31

7.1

3.9

7.39

7.40

0.43

278

(3016407) Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay

3.00

2.26

6.4

4.3

3.58

3.67

g/l

—

(3027529) Toxoplasma gondii IgM Ab [Units/volume] in Serum

5.71

2.23

1.2

1.4

—

(3021601) Nitrite [Presence] in Urine by Test strip

659

1.65

2.14

5.6

3.9

0.00

estimate

-0.00

140

(3014959) Toxoplasma gondii IgG Ab [Units/volume] in Serum

5.14

2.09

2.4

2.7

—

(3035350) Ketones [Presence] in Urine by Test strip

669

1.60

1.94

5.6

3.9

0.00

11.36

estimate

0.50

143

(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count

203

1.75

1.91

3.5

3.2

3.59

2.44

e6/l

0.29

(3026008) Bacteria identified in Urine by Culture

376

1.61

1.90

4.6

3.2

—

(3024561) Albumin [Mass/volume] in Serum or Plasma

563

1.58

1.90

8.0

4.7

36.09

35.66

g/l

0.28

541

(3008486) Thyroxine (T4) free [Moles/volume] in Serum or Plasma

107

921

1.72

1.90

4.7

4.5

15.03

14.81

pmol/l

0.47

853

(3009261) Glucose [Presence] in Urine by Test strip

672

1.59

1.88

5.6

3.9

0.00

estimate

-0.00

130

(3023520) Reticulocytes [#/volume] in Blood

110

1.96

1.85

2.3

3.7

68.96

72.62

e9/l

0.24

(3016431) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma

635

1.57

1.82

12.6

7.2

1.21

mmol/l

0.42

545

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

559

1.56

1.78

2.4

2.2

89.83

94.66

pmol/l

0.25

286

(3027945) Reticulocytes/Erythrocytes in Blood

151

1.80

1.75

4.4

3.5

1.79

1.85

0.17

135

(3002256) Pathology report gross observation

161

1.76

1.68

1.1

1.2

—

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

2.11

1.66

1.9

1.7

—

(3025839) Triglyceride [Moles/volume] in Serum or Plasma

492

1.52

1.59

2.0

1.28

1.36

mmol/l

0.32

412

(3011371) Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection

2.13

1.48

2.4

2.5

—

(3007628) Bicarbonate [Moles/volume] standard in Venous blood

1.96

1.47

3.7

6.4

24.66

24.44

mmol/l

0.15

(3000515) Antithrombin actual/normal in Platelet poor plasma by Chromogenic method

2.34

1.43

6.0

3.7

93.22

91.85

—

(3010130) Cytomegalovirus IgG Ab [Units/volume] in Serum or Plasma

2.68

1.38

1.5

1.4

—

166.40

—

(4024509) Urine culture

2.06

1.37

2.3

1.9

—

(3008898) HLA-B27 [Presence]

2.22

1.36

1.2

1.1

—

(3013650) Neutrophils [#/volume] in Blood by Automated count

722

1.46

1.33

14.5

10.9

4.20

4.13

e9/l

0.12

627

(3017918) Cytomegalovirus IgG Ab [Titer] in Serum or Plasma

2.57

1.32

2.2

1.5

—

(3015635) Cytomegalovirus IgM Ab [Units/volume] in Serum or Plasma

2.57

1.32

1.5

1.4

—

(3007844) Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay

2.57

1.32

1.8

1.3

—

(3019250) Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay

2.43

1.31

7.1

4.5

205.63

205.15

—

(40771025) 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma

555

1.44

1.31

3.5

2.5

81.95

77.91

nmol/l

0.37

501

(40768804) Tissue Pathology biopsy report

498

1.44

1.30

2.4

2.0

—

(3041096) Erythrocytes [Presence] in Urine by Automated

368

1.47

1.28

5.1

3.3

0.00

estimate

-0.00

108

(3003396) Base excess in Arterial blood by calculation

143

1.64

1.21

14.5

8.3

0.41

0.96

mmol/l

0.34

119

(3021614) Rheumatoid factor [Units/volume] in Serum or Plasma

228

1.53

1.20

1.7

1.3

9.52

30.67

iu/ml

—

(4035726) Immunohistochemistry procedure

127

1.67

1.19

1.3

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

731

1.42

1.19

4.0

3.2

—

(3012544) pH of Venous blood

144

1.63

1.18

4.4

5.1

7.37

7.39

0.49

(3029937) Albumin [Presence] in Urine by Test strip

355

1.44

1.17

5.0

4.1

0.00

estimate

-0.00

126

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

492

1.39

1.08

5.6

3.8

0.00

0.01

estimate

0.50

115

(3009035) Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma

243

1.47

1.06

1.6

1.8

225000395.68

470.02

pmol/l

0.49

201

(3019977) pH of Arterial blood

140

1.59

1.05

15.0

8.4

7.41

0.01

(3029713) Protein.monoclonal band 1 [Mass/volume] in Serum or Plasma by Electrophoresis

1.98

1.04

1.9

2.4

0.00

0.49

g/l

—

(3019198) Lymphocytes [#/volume] in Blood

652

1.37

1.02

10.7

6.6

2.39

1.87

e9/l

0.44

572

(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum

211

1.47

0.99

1.6

1.3

1.05

9.11

u/ml

1.67

(3042936) Bacteria identified in Isolate by Culture

185

1.50

0.99

1.8

1.9

—

(3006315) Basophils [#/volume] in Blood

646

1.35

0.96

10.7

6.6

0.04

e9/l

0.07

548

(46237023) Hepatitis B virus core and surface Ab and surface Ag panel - Serum

1.94

0.95

1.3

1.2

—

(3013115) Eosinophils [#/volume] in Blood

668

1.35

0.93

12.4

6.9

0.17

0.19

e9/l

0.32

580

(3001604) Monocytes [#/volume] in Blood

641

1.33

0.89

10.8

6.6

0.59

0.57

e9/l

0.23

545

(3029511) Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection

1.91

0.89

1.5

1.7

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

136

0.56

0.89

2.1

1.5

—

(3019832) Treponema pallidum Ab [Presence] in Serum

121

1.56

0.88

2.1

1.8

—

(3009508) Creatinine [Moles/volume] in Urine

430

1.34

0.85

4.4

2.9

7.32

7.88

mmol/l

0.38

371

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

1.64

0.85

2.1

1.4

—

(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection

1.71

0.84

2.9

2.5

—

(3000494) Fungus identified in Specimen by Culture

157

1.48

0.83

1.8

1.4

—

(3005702) Mycobacterium sp identified in Specimen by Organism specific culture

1.91

0.83

2.3

1.5

—

(3006184) Hemoglobin [Mass/volume] in Capillary blood

1.91

0.83

3.3

2.1

118.83

120.16

g/l

—

(3049804) Myeloperoxidase IgG Ab [Units/volume] in Serum

1.91

0.83

1.3

1.0

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

123

1.53

0.82

5.8

3.2

—

(40764999) Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M

121

1139

1.51

0.80

23.6

15.9

79.05

80.74

ml/min/173m2

0.36

110

1051

(1761482) Bacteria [#/volume] in Urine by Culture

1.80

0.77

9.7

5.1

—

(3016650) Hepatitis A virus Ab [Presence] in Serum

2.22

0.77

1.4

1.0

—

(1616796) Gas panel - Central venous blood

2.22

0.77

9.0

2.2

—

(40769539) Bacteria identified based on 16S rRNA gene [Identifier] in Specimen by Sequencing

2.12

0.75

2.0

1.7

—

(3001019) Free T4 and TSH panel - Serum or Plasma

1.65

0.74

1.8

2.1

—

(3009201) Thyrotropin [Units/volume] in Serum or Plasma

116

1088

1.42

0.74

6.2

5.6

1.72

1.95

mu/l

1.80

107

1006

(3013327) Hepatitis A virus IgM Ab [Presence] in Serum

2.04

0.73

1.2

1.0

—

(3048929) Epstein Barr virus Ab [Presence] in Serum

1.74

0.71

1.7

1.4

—

(3003191) Choriogonadotropin [Presence] in Serum or Plasma

1.74

0.71

2.7

2.3

—

(3029338) Protein.monoclonal band 3 [Mass/volume] in Serum or Plasma by Electrophoresis

1.74

0.71

2.0

2.3

0.00

g/l

—

(3035933) Granulocytes/Leukocytes in Blood

1.81

0.67

1.4

1.9

51.80

59.04

—

(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection

1.62

0.66

1.1

1.3

—

(3012516) Albumin [Mass/volume] in Urine

397

1.28

0.64

4.4

3.1

24.59

41.25

mg/l

0.62

262

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

175

1.38

0.63

1.3

1.5

—

(3009445) Proteinase 3 Ab [Units/volume] in Serum

1.67

0.63

1.3

1.1

—

(1002224) Polysomnography panel

1.57

0.61

1.0

1.1

—

(3008757) Leukocyte morphology finding [Identifier] in Blood

0.00

0.60

0.0

5.3

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

150

1.39

0.60

3.0

1.9

—

(3032080) INR in Blood by Coagulation assay

575

1.25

0.60

20.9

13.0

1.27

1.23

inr

0.18

474

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

159

1.38

0.60

2.9

1.8

—

(3016921) Smith extractable nuclear Ab [Units/volume] in Serum

1.75

0.58

1.2

1.3

—

4.00

—

(3019060) Gas panel - Arterial blood

1.55

0.58

3.5

3.3

—

(3019150) Specific gravity of Urine by Refractometry

279

1.29

0.58

4.9

4.2

1.01

1.02

kg/l

1.78

186

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

116

1.43

0.57

2.7

2.1

—

(3015377) Calcium [Moles/volume] in Serum or Plasma

451

1.25

0.56

4.5

3.1

2.36

mmol/l

0.08

402

(3000991) Gas panel - Venous blood

117

1.42

0.55

17.6

9.6

—

(3014162) Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection

1.60

0.55

5.0

2.3

—

(3028626) Oxygen [Partial pressure] in Capillary blood

1.60

0.55

3.0

2.0

9.15

8.29

kpa

—

(40758558) Short blood count panel - Blood

405

1.24

0.54

8.5

7.1

—

(3000764) Benzodiazepines [Presence] in Urine

1.52

0.52

1.5

1.4

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

602

1.22

0.51

3.2

2.9

—

estimate

—

(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting

117

1116

1.32

0.50

5.1

4.4

1.32

1.27

mmol/l

0.31

104

1031

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

129

1.36

0.48

3.5

2.3

—

(3019309) Folate [Moles/volume] in Red Blood Cells

212

1.28

0.46

2.0

1.6

1072.95

1125.52

nmol/l

0.11

161

(3050238) Crystals [Presence] in Synovial fluid by Light microscopy

1.64

0.43

1.0

1.2

—

(3011288) Drugs identified in Urine by Screen method Nominal

1.58

0.42

1.2

1.8

—

(21494890) Protein electrophoresis panel - 24 hour Urine

0.00

0.41

0.0

1.5

—

(3020460) C reactive protein [Mass/volume] in Serum or Plasma

123

1188

1.33

0.41

26.6

16.6

21.59

23.89

mg/l

0.42

106

986

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

282

1.22

0.40

5.1

4.3

25.28

21.64

0.73

132

(3003458) Phosphate [Moles/volume] in Serum or Plasma

161

1.28

0.40

16.6

5.5

1.08

1.04

mmol/l

0.26

151

(3024928) Oxygen saturation in Venous blood

1.40

0.38

1.6

7.1

58.50

57.91

—

(3016879) Cocaine [Presence] in Urine

1.48

0.36

1.3

—

(3027944) Amphetamines [Presence] in Urine

1.48

0.36

1.5

1.3

—

(3027008) Opiates [Presence] in Urine

1.45

0.36

1.5

1.3

—

(3028300) Cannabinoids [Presence] in Urine

1.45

0.36

1.5

1.4

—

(3018251) Fasting glucose [Moles/volume] in Serum or Plasma

120

1160

1.26

0.36

6.3

5.1

5.94

5.92

mmol/l

0.06

109

1068

(3020682) Albumin/Creatinine [Ratio] in Urine

411

1.18

0.36

5.7

3.7

4.47

6.59

mg/mmol

0.28

264

(3010156) C reactive protein [Mass/volume] in Serum or Plasma by High sensitivity method

1.32

0.33

1.8

1.5

6.48

4.04

mg/l

—

(3006217) Methemoglobin/Hemoglobin.total in Arterial blood

1.35

0.33

21.7

10.1

0.76

0.70

0.21

(3005322) IgE [Units/volume] in Serum or Plasma

1.35

0.33

1.4

1.1

101.15

327.95

u/ml

0.65

(3022145) Colonoscopy Study observation

147

1.26

0.32

1.3

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

483

1.16

0.32

5.9

4.0

22.59

40.82

ng/l

1.03

341

(3020564) Creatinine [Moles/volume] in Serum or Plasma

128

1250

1.33

0.31

30.5

21.4

80.45

76.73

umol/l

0.47

128

1237

(3028653) Carboxyhemoglobin/Hemoglobin.total in Arterial blood

1.34

0.31

21.7

10.1

1.51

1.28

0.46

(3023602) Cholesterol in HDL [Moles/volume] in Serum or Plasma

120

1164

1.24

0.31

5.9

5.1

1.41

1.49

mmol/l

1.44

108

1080

(36660697) Celiac disease serology panel - Serum

116

0.76

0.29

1.2

—

(3005013) Prostate Specific Ag Free [Mass/volume] in Serum or Plasma

217

1.19

0.27

3.5

3.1

0.75

ug/l

0.01

125

(3023368) Bacteria identified in Blood by Culture

342

1.15

0.27

10.4

4.7

—

(3021337) Troponin I.cardiac [Mass/volume] in Serum or Plasma

237

1.17

0.25

4.3

3.8

397.67

178.95

ng/l

0.32

178

(3024889) Methemoglobin/Hemoglobin.total in Venous blood

1.30

0.25

2.0

4.8

0.75

0.64

—

(3019900) Cholesterol [Moles/volume] in Serum or Plasma

120

1170

1.20

0.24

6.2

5.2

4.49

4.62

mmol/l

0.83

109

1091

(3015235) Bicarbonate [Moles/volume] in Capillary blood

1.36

0.24

2.4

2.0

25.96

24.95

mmol/l

—

(3014576) Chloride [Moles/volume] in Serum or Plasma

191

1.18

0.23

16.0

8.2

106.41

103.86

mmol/l

1.72

191

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

125

1.22

0.23

7.3

7.0

—

(40768793) Breast Pathology biopsy report

1.33

0.23

1.2

—

(3004588) Protein electrophoresis panel - Serum or Plasma

1.27

0.23

1.9

2.3

—

(1761868) Lipid panel - Serum or Plasma

456

0.89

0.22

4.5

3.1

—

(3019050) Tissue transglutaminase IgA Ab [Units/volume] in Serum

312

0.87

0.22

1.4

1.3

1.81

1.63

u/ml

—

(40761536) Microorganisms panel - Urine sediment

1.26

0.21

7.2

3.1

—

(3001405) CD3+CD8+ (T8 suppressor) cells [#/volume] in Blood

0.00

0.21

0.0

6.0

—

601.00

—

(3017817) Protein [Mass] in Urine collected for unspecified duration

0.00

0.21

0.0

1.3

—

362.73

—

(3035999) Lactate [Moles/volume] in Cerebral spinal fluid

0.00

0.21

0.0

1.1

—

2.05

—

(3012158) Parainfluenza virus 2 RNA [Presence] in Specimen by NAA with probe detection

0.00

0.21

0.0

2.0

—

(3006262) Parainfluenza virus 3 RNA [Presence] in Specimen by NAA with probe detection

0.00

0.21

0.0

2.0

—

(3038297) Parainfluenza virus 4 RNA [Presence] in Specimen by NAA with probe detection

0.00

0.21

0.0

2.0

—

(3025634) Parainfluenza virus 1 RNA [Presence] in Specimen by NAA with probe detection

0.00

0.21

0.0

2.0

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

212

1.16

0.21

3.3

2.0

—

(3016436) Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma

0.00

0.21

0.0

4.3

—

218.33

—

(3016914) Bacteria identified in Cerebral spinal fluid by Culture

0.00

0.21

0.0

1.1

—

(3010517) Carboxyhemoglobin/Hemoglobin.total in Venous blood

1.27

0.21

2.0

4.8

1.30

1.21

—

(37019628) Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection

1.23

0.20

1.0

1.3

—

(21494755) Public health laboratory ask at order entry panel

121

0.81

0.18

1.7

1.3

—

(43534045) MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal

0.78

0.16

1.0

—

(3001308) Cholesterol in LDL [Moles/volume] in Serum or Plasma

121

1190

1.14

0.14

6.9

5.9

2.63

2.70

mmol/l

0.44

112

1109

(3013139) Helicobacter pylori Ag [Presence] in Stool

1.18

0.11

1.2

1.3

—

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

115

1.14

0.11

1.4

1.8

—

(3001334) Neutrophil cytoplasmic Ab [Units/volume] in Serum

1.09

0.09

1.6

1.1

—

(40768797) Stomach Pathology biopsy report

175

1.10

0.09

1.5

1.3

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

327

0.93

0.08

3.2

2.5

—

(3025941) Bacteria identified in Stool by Culture

1.04

0.08

1.8

1.3

—

(40768443) Skin Pathology biopsy report

1.04

0.08

1.0

1.3

—

(3007164) IgA [Mass/volume] in Serum or Plasma

286

0.93

0.08

1.7

1.5

2.30

2.60

g/l

0.24

165

(3026910) Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma

822

1.06

0.08

4.8

3.3

57.48

46.13

u/l

0.54

790

(3005785) Creatine kinase.MB [Mass/volume] in Serum or Plasma

112

0.88

0.07

3.1

2.6

4.29

7.99

ug/l

—

(3007461) Platelets [#/volume] in Blood

129

1280

1.12

0.06

37.9

25.3

254.96

251.33

e9/l

0.24

124

1264

(3017143) Hepatitis C virus Ab [Presence] in Serum

150

1.08

0.04

2.9

1.7

—

(3044640) Blood type and Crossmatch panel - Blood

431

0.96

0.03

3.1

2.5

—

(40760892) CBC W Ordered Manual Differential panel - Blood

280

1.05

0.03

12.1

4.5

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

229

0.95

0.03

3.9

2.0

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

231

1.05

0.03

2.0

1.7

—

(4010399) Spirometry for bronchospasm with prolonged evaluation after bronchodilator

103

1.07

0.02

1.7

1.4

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

1.07

0.01

1.7

1.6

—

(3000492) Spirometry study

141

0.99

0.00

2.9

1.6

—

(3029187) Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma

389

1.00

0.00

4.9

3.2

2024.24

1247.91

ng/l

0.71

324

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

193

0.98

0.00

2.9

1.7

—

(3003694) ABO and Rh group [Type] in Blood

363

0.99

0.00

1.5

—

(40761511) CBC panel - Blood by Automated count

123

1228

1.01

0.00

22.6

14.3

—

(3007853) Bacteria identified in Skin by Aerobe culture

145

1.04

0.00

1.5

1.7

—

(3004716) Salmonella sp identified in Stool by Organism specific culture

0.89

0.00

1.7

1.4

—

(3022914) Cancer Ag 19-9 [Units/volume] in Serum or Plasma

0.84

0.00

3.2

3.9

14.80

2936.77

u/ml

—

(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection

0.00

-0.00

0.0

1.1

—

(3008536) Aspergillus sp Ab [Presence] in Serum

0.00

-0.00

0.0

1.6

—

(3033386) Bacteria [Presence] in Cerebral spinal fluid by Light microscopy

0.00

-0.00

0.0

1.0

—

(3046896) Herpes virus 6 DNA [Presence] in Cerebral spinal fluid by NAA with probe detection

0.00

-0.00

0.0

1.2

—

(40765096) Chromosome analysis panel by Banding

0.00

-0.00

0.0

1.0

—

(3027953) Aldolase [Enzymatic activity/volume] in Serum or Plasma

0.00

-0.00

0.0

1.2

—

12.05

—

(3048879) Bone marrow aspiration report

0.00

-0.00

0.0

4.0

—

(3018301) Testosterone Free [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.0

—

177.63

—

(3034603) RHD gene allele [Genotype] in Blood or Tissue by Molecular genetics method Nominal

0.00

-0.00

0.0

1.2

—

(3026989) Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma

0.97

-0.00

1.3

3.7

4.43

4.57

pmol/l

—

(3028433) Virus identified in Specimen by Culture

0.00

-0.00

0.0

1.3

—

(3030429) Borrelia sp DNA [Identifier] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.0

—

(3047189) Immunofixation for 24 hour Urine

0.00

-0.00

0.0

1.3

—

(36305771) Cryptosporidium sp DNA [Presence] in Stool by NAA with probe detection

0.00

-0.00

0.0

1.0

—

(3023709) Somatotropin [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

1.6

—

1.79

—

(3010813) Leukocytes [#/volume] in Blood

129

1281

1.11

-0.00

37.8

25.4

7.23

6.75

e9/l

0.44

124

1261

(3022313) Gas panel - Capillary blood

0.86

-0.00

8.4

2.5

—

(3022058) Hepatitis B virus DNA [Presence] in Serum or Plasma by NAA with probe detection

0.00

-0.00

0.0

1.4

—

(3020650) Glucose [Presence] in Urine

0.00

-0.00

0.0

1.5

—

0.00

—

(3020911) Cortisol [Moles/time] in 24 hour Urine

0.00

-0.00

0.0

1.8

—

52.83

—

(3049506) Microalbumin [Mass/time] in Urine collected for unspecified duration

0.00

-0.00

0.0

1.8

—

(40758292) HTLV I+II Ab panel - Serum

0.00

-0.00

0.0

1.5

—

(3009343) pH of Capillary blood

0.99

-0.00

6.3

2.5

7.43

7.42

—

(37208534) Antinuclear antibody arbitrary concentration in serum

0.00

-0.00

0.0

1.0

—

(3015024) Glucose [Moles/volume] in Serum or Plasma --1 hour post dose glucose

0.00

-0.00

0.0

1.7

—

7.20

—

(3008733) Herpes simplex virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection

0.00

-0.00

0.0

1.0

—

(3036603) Volume of Urine

0.00

-0.00

0.0

1.8

—

1768.13

—

(3017704) Immunofixation for Urine

0.00

-0.00

0.0

3.0

—

(40761535) Cells panel - Urine sediment

0.93

-0.00

5.1

3.4

—

(3002619) Bacteria identified in Specimen by Culture

0.00

-0.00

0.0

1.3

—

(3026515) Parvovirus B19 IgM Ab [Units/volume] in Serum

0.00

-0.00

0.0

1.3

—

(37021247) Adenovirus 40+41 DNA [Presence] in Stool by NAA with probe detection

0.00

-0.00

0.0

1.1

—

(3030558) Cytomegalovirus DNA [Units/volume] (viral load) in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.7

—

(3006653) Thiamine [Moles/volume] in Blood

0.00

-0.00

0.0

2.0

—

132.00

—

(3036535) Thyroglobulin [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

3.4

—

21.50

—

(3045683) HLA typing for celiac disease panel - Blood or Tissue

0.00

-0.00

0.0

1.0

—

(3011960) Natriuretic peptide B [Mass/volume] in Serum or Plasma

0.94

-0.00

3.9

3.5

346.63

157.79

ng/l

—

(40771527) Human papilloma virus E6+E7 mRNA [Presence] in Cervix by NAA with probe detection

0.00

-0.00

0.0

2.3

—

(37020445) Astrovirus RNA [Presence] in Stool by NAA with probe detection

0.00

-0.00

0.0

1.1

—

(3032567) Hepatitis B virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection

0.00

-0.00

0.0

3.2

—

(3000108) Respiratory syncytial virus B RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

2.1

—

(21493195) Respiratory pathogens DNA and RNA tested for in Respiratory system specimen by NAA with probe detection

0.00

-0.00

0.0

2.1

—

(3026361) Erythrocytes [#/volume] in Blood

129

1281

1.11

-0.00

37.8

25.3

4.45

4.46

e12/l

0.11

124

1260

(3005082) Progesterone [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.0

—

33.34

—

(37020937) Giardia lamblia DNA [Presence] in Stool by NAA with probe detection

0.00

-0.00

0.0

1.0

—

(3021197) Magnesium Ionized [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

2.0

—

0.59

—

(3006442) Creatine [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

2.3

—

70.33

—

(3013566) Clostridioides difficile [Presence] in Stool by Organism specific culture

0.00

-0.00

0.0

1.2

—

(3005156) Respiratory syncytial virus A RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

2.1

—

(3049539) Genetic diseases [Identifier] in Blood or Tissue by FISH Nominal

0.00

-0.00

0.0

1.1

—

Mortality – FinRegistry

↥

Association

Association between endpoint H7_CHORSCAR and mortality.

Females

Parameter	HR [95% CI]	p-value
H7_CHORSCAR	1.083 [0.82, 1.43]	0.579
Birth year	0.995 [0.99, 1.0]	0.218

During the follow-up period (1.1.1998 — 31.12.2019), 63 out of 382 females with H7_CHORSCAR died.

Males

Parameter	HR [95% CI]	p-value
H7_CHORSCAR	0.918 [0.68, 1.23]	0.57
Birth year	0.992 [0.98, 1.0]	0.071

During the follow-up period (1.1.1998 — 31.12.2019), 59 out of 360 males with H7_CHORSCAR died.

Mortality risk

Mortality risk for people of age

years, who have H7_CHORSCAR.

N-year risk	Females	Males
1	0.086%	0.217%
5	0.547%	1.201%
10	1.513%	2.911%
15	2.959%	6.027%
20	5.279%	10.064%

Relationships between endpoints

↥

Index endpoint: H7_CHORSCAR – Chorioretinal scars

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Chorioretinal scars

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

Matched cohort

TimeCodeWAS

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints